Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Fuji
QuintilesIMS
Healthtrust
McKinsey
Mallinckrodt
Cerilliant
Dow

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,723,303

« Back to Dashboard

Which drugs does patent 6,723,303 protect, and when does it expire?

Patent 6,723,303 protects OPTISON and is included in one NDA.

This patent has thirty-nine patent family members in twenty-seven countries.
Summary for Patent: 6,723,303
Title: Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
Abstract:Agents for use in ultrasound contrast include protein microspheres in which a gas such as perfluoropropane, perfluorobutane or perfluoropentane is contained.
Inventor(s): Quay; Steven C (Pacific Palisades, CA)
Assignee: Amersham Health, AS (Oslo, NO)
Application Number:08/466,104
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 6,723,303

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,723,303

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,558,094 Methods for using persistent gases as ultrasound contrast media ➤ Sign Up
5,393,524 Methods for selecting and using gases as ultrasound contrast media ➤ Sign Up
5,573,751 Persistent gaseous bubbles as ultrasound contrast media ➤ Sign Up
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
US Army
Queensland Health
Dow
Julphar
Merck
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.